Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02247986
Recruitment Status : Withdrawn
First Posted : September 25, 2014
Last Update Posted : September 6, 2019
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) )

Brief Summary:

Background:

- Disruptive behavior is a common problem for children and adolescents. It can be treated with some success with stimulant medicine. Researchers want to learn more about how this works.

Objective:

- To learn how the brain changes when taking the medicine methylphenidate for behavior problems.

Eligibility:

  • Children ages 10 17 with conduct disorder and/or attention deficit disorder.
  • Healthy volunteers the same age.

Design:

  • Participants will be screened under a separate protocol.
  • Participants will have two 3-hour sessions at the clinic. Girls who are menstruating will have a pregnancy test before their scans.
  • Visit 1: All participants will:
  • Perform simple tests on a computer.
  • Fill out a questionnaire along with their parent or guardian.
  • Have an MRI scan. A magnetic field and radio waves take pictures of the brain. Participants will lie on a table that slides into a metal cylinder. A coil will be placed over their head. They will be in the scanner for 60 minutes, lying still or performing a simple task. They will practice the task before the scan. A computer screen will show them task information during the scan. The scanner makes loud knocking sounds. Participants will get earplugs. Their parent or guardian can stay with them during the scan.
  • Only participants with behavior disorders will:
  • Take a pill of the study medicine or placebo.
  • Be monitored for any side effects.
  • Visit 2 is a repeat of Visit 1, except participants who got a pill in Visit 1 will get the other pill in Visit 2. For healthy volunteers, the 2 visits are exactly the same.

Condition or disease Intervention/treatment Phase
Conduct Disorder Attention Defict Hyperactivity Disorder Drug: Methylphenidate Hydrochloride Phase 1 Phase 2

Detailed Description:

OBJECTIVE:

To determine the impact, as indexed by BOLD response, of the administration of dopaminergic agonist (methylphenidate) on the pathophysiology of CD/ODD.

STUDY POPULATION:

Youth with CD/ODD and typically developing (TD) youth.

DESIGN:

The study will involve a 2 session design (methylphenidate [MPH] vs. placebo). Patients with CD/ODD will participate in both sessions. TD youth will be tested for 2 sessions (no medication) to provide an index of typical task response. Activity within regions of interest identified from the TD youth will be used to determine whether MPH reduces differences in BOLD response in CD/ODD relative to TD youth. ICU scores and current ADHD symptomatology will be used as covariates to determine whether these variables moderate the putative increase in BOLD response in target regions in the patients with CD.

OUTCOME MEASURES:

Principle dependent measures will be BOLD responses as measured through core tasks.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Other
Official Title: Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder
Study Start Date : September 4, 2014
Actual Primary Completion Date : May 18, 2015
Actual Study Completion Date : May 18, 2015

Resource links provided by the National Library of Medicine



Intervention Details:
  • Drug: Methylphenidate Hydrochloride
    Bold signal changes by methylphenidate on DBD


Primary Outcome Measures :
  1. Patients with CD will show an increase in the amygdala response to fearful expressions such that the difference between BOLD response in patients and TDs is reduced on MPH relative to placebo. ICU score will be a significant covariate of the inc... [ Time Frame: 2 years from the initiation of the protocol ]
  2. Patients with CD will show an increase in reward prediction errors and reward expected value signaling within striatum and ventromedial frontal cortex (vmPFC) such that the difference between BOLD response in patients and TDs is reduced on MPH r... [ Time Frame: 2 years from the initiation of the protocol ]
  3. Patients with CD will show an increase in conflict related signaling within dorsomedial, lateral and parietal cortices such that the difference between BOLD response in patients and TDs is reduced on MPH relative to placebo. Current ADHD sympto... [ Time Frame: 2 years from the initiation of the protocol ]

Secondary Outcome Measures :
  1. Symptom profiles measured by the clinical scales listed in the protocol (CBCL, the ICU, Connor s parent report on ADHD symptom) will be significantly related to the BOLD signal changes after methylphenidate administration. [ Time Frame: 2 years from the initiation of the protocol ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA

Youth with CD

  1. 10-17 years of age.
  2. A current diagnosis of CD as determined by the Kiddie-SADS, lifetime version.

    • Youth in the CD+comorbid ADHD group will also meet diagnostic criteria for ADHD.
    • Youth in the CD without comorbid ADHD group will specifically not meet diagnostic criteria for ADHD.
  3. Youth with CD shouldmust be na(SqrRoot) ve to psychoactive medication (such as: methylphenidate and amphetamine).

TD youth

  1. 10-17 years of age.
  2. No current psychiatric diagnosis, as determined by the Kiddie-SADS, lifetime version.

EXCLUSION CRITERIA

Exclusion criteria for youth with CD (with or without ADHD)

  1. Comorbid psychotic, major mood, tic, pervasive developmental, and substance abuse disorders.
  2. Presence of comorbid ADHD is exclusory for the group of patients with CD without ADHD
  3. History of known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems
  4. Current weight less than 25kg or over 90kg

Exclusion criteria for all participants (CD with ADHD, CD without ADHD and TD)

  1. History of serious CNS disease disorder (examples aresuch as: history of seizure, epilepsy, brain tumor, brain hemorrhage, and major CNS infection such as meningitis or encephalitis)
  2. Previous history of known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems
  3. Current use of any psychiatric medications and centrally acting medications (such as stimulants, non-stimulant ADHD medications, antidepressants, anxiolytics, antipsychotics and anti-epilepsy medications), and past history of use of psychoactive medication (such as methylphenidate and amphetamine)
  4. A positive urine pregnancy test
  5. A Positive urine toxicology, History/current diagnosis of substance abuse/dependence
  6. Suicidal or homicidal ideation within the past 6 months.
  7. Wechsler Abbreviated Scale of Intelligence (WASI) (D. Wechsler, 1999) scores <70
  8. Metal in body (i.e., hearing aid, cardiac pacemaker, bone plates, etc), claustrophobia, or any other condition that would preclude fMRI scanning.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02247986


Sponsors and Collaborators
National Institute of Mental Health (NIMH)
Investigators
Layout table for investigator information
Principal Investigator: James J Blair, Ph.D. National Institute of Mental Health (NIMH)

Publications:
Layout table for additonal information
Responsible Party: National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT02247986     History of Changes
Other Study ID Numbers: 140193
14-M-0193
First Posted: September 25, 2014    Key Record Dates
Last Update Posted: September 6, 2019
Last Verified: May 18, 2015
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) ):
Conduct Disorder
Methylphenidate
Disruptive Behavior Disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Methylphenidate
Disease
Conduct Disorder
Problem Behavior
Pathologic Processes
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Behavioral Symptoms
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents